BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it is offering to sell, subject to market and other conditions, 9,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Seattle Genetics also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 1,350,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by Seattle Genetics. J.P. Morgan Securities Inc. and Goldman, Sachs & Co. are acting as joint book-running managers of the proposed offering.
